Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.

Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ.

Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. No abstract available.

2.

Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans.

Mooij HL, Bernelot Moens SJ, Gordts PL, Stanford KI, Foley EM, van den Boogert MA, Witjes JJ, Hassing HC, Tanck MW, van de Sande MA, Levels JH, Kastelein JJ, Stroes ES, Dallinga-Thie GM, Esko JD, Nieuwdorp M.

J Lipid Res. 2015 Mar;56(3):665-73. doi: 10.1194/jlr.M053504. Epub 2015 Jan 7.

3.

Carriers of loss-of-function mutations in EXT display impaired pancreatic beta-cell reserve due to smaller pancreas volume.

Bernelot Moens SJ, Mooij HL, Hassing HC, Kruit JK, Witjes JJ, van de Sande MA, Nederveen AJ, Xu D, Dallinga-Thie GM, Esko JD, Stroes ES, Nieuwdorp M.

PLoS One. 2014 Dec 26;9(12):e115662. doi: 10.1371/journal.pone.0115662. eCollection 2014.

4.

Loss of function in heparan sulfate elongation genes EXT1 and EXT 2 results in improved nitric oxide bioavailability and endothelial function.

Mooij HL, Cabrales P, Bernelot Moens SJ, Xu D, Udayappan SD, Tsai AG, van der Sande MA, de Groot E, Intaglietta M, Kastelein JJ, Dallinga-Thie GM, Esko JD, Stroes ES, Nieuwdorp M.

J Am Heart Assoc. 2014 Dec 2;3(6):e001274. doi: 10.1161/JAHA.114.001274.

5.

SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus.

Hassing HC, Surendran RP, Derudas B, Verrijken A, Francque SM, Mooij HL, Bernelot Moens SJ, Hart LM, Nijpels G, Dekker JM, Williams KJ, Stroes ES, Van Gaal LF, Staels B, Nieuwdorp M, Dallinga-Thie GM.

Obesity (Silver Spring). 2014 May;22(5):1309-16. doi: 10.1002/oby.20682. Epub 2014 Jan 9.

6.

Rapid insulin-mediated increase in microvascular glycocalyx accessibility in skeletal muscle may contribute to insulin-mediated glucose disposal in rats.

Eskens BJ, Mooij HL, Cleutjens JP, Roos JM, Cobelens JE, Vink H, Vanteeffelen JW.

PLoS One. 2013;8(1):e55399. doi: 10.1371/journal.pone.0055399. Epub 2013 Jan 31.

7.

Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.

Hassing HC, Mooij H, Guo S, Monia BP, Chen K, Kulik W, Dallinga-Thie GM, Nieuwdorp M, Stroes ES, Williams KJ.

Hepatology. 2012 Jun;55(6):1746-53. doi: 10.1002/hep.25580.

8.

Pathophysiology of hypertriglyceridemia.

Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM.

Biochim Biophys Acta. 2012 May;1821(5):826-32. doi: 10.1016/j.bbalip.2011.11.010. Epub 2011 Dec 10. Review.

PMID:
22179026
9.

Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus.

Broekhuizen LN, Lemkes BA, Mooij HL, Meuwese MC, Verberne H, Holleman F, Schlingemann RO, Nieuwdorp M, Stroes ES, Vink H.

Diabetologia. 2010 Dec;53(12):2646-55. doi: 10.1007/s00125-010-1910-x. Epub 2010 Sep 25.

10.

The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight.

Dallinga-Thie GM, Franssen R, Mooij HL, Visser ME, Hassing HC, Peelman F, Kastelein JJ, Péterfy M, Nieuwdorp M.

Atherosclerosis. 2010 Jul;211(1):1-8. doi: 10.1016/j.atherosclerosis.2009.12.027. Epub 2009 Dec 29. Review.

11.

Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease.

Broekhuizen LN, Mooij HL, Kastelein JJ, Stroes ES, Vink H, Nieuwdorp M.

Curr Opin Lipidol. 2009 Feb;20(1):57-62. doi: 10.1097/MOL.0b013e328321b587. Review.

PMID:
19106708
12.

Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia.

Meuwese MC, Mooij HL, Nieuwdorp M, van Lith B, Marck R, Vink H, Kastelein JJ, Stroes ES.

J Lipid Res. 2009 Jan;50(1):148-53. doi: 10.1194/jlr.P800025-JLR200. Epub 2008 Aug 11.

13.

Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation.

Nieuwdorp M, Meuwese MC, Mooij HL, van Lieshout MH, Hayden A, Levi M, Meijers JC, Ince C, Kastelein JJ, Vink H, Stroes ES.

Atherosclerosis. 2009 Jan;202(1):296-303. doi: 10.1016/j.atherosclerosis.2008.03.024. Epub 2008 Apr 12.

PMID:
18550063
14.

Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability.

Nieuwdorp M, Meuwese MC, Mooij HL, Ince C, Broekhuizen LN, Kastelein JJ, Stroes ES, Vink H.

J Appl Physiol (1985). 2008 Mar;104(3):845-52. Epub 2007 Dec 27.

15.

Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes.

Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, Ince C, Holleman F, Diamant M, Heine RJ, Hoekstra JB, Kastelein JJ, Stroes ES, Vink H.

Diabetes. 2006 Apr;55(4):1127-32.

16.

Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.

Nieuwdorp M, van Haeften TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, Meijers JC, Holleman F, Hoekstra JB, Vink H, Kastelein JJ, Stroes ES.

Diabetes. 2006 Feb;55(2):480-6.

17.

Physics. The road to quantum computing.

Mooij H.

Science. 2005 Feb 25;307(5713):1210-1. No abstract available.

PMID:
15731432
18.

Visualising scanning patterns of pathologists in the grading of cervical intraepithelial neoplasia.

Tiersma ES, Peters AA, Mooij HA, Fleuren GJ.

J Clin Pathol. 2003 Sep;56(9):677-80.

Supplemental Content

Support Center